论文部分内容阅读
目的观察依折麦布联合普伐他汀对急性冠脉综合征患者血脂和高敏C反应蛋白(hs-CRP)的影响。方法急性冠脉综合征患者80例,分为观察组42例,给普伐他汀20 mg.d-1联合依折麦布10 mg.d-1;对照组38例,给普伐他汀20 mg.d-1,2组均治疗30 d。检测2组患者治疗前,治疗d 7、d 30血脂和高敏C反应蛋白。2组治疗前后组内及组间进行对比分析。结果治疗d 7观察组胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)与治疗前比较有明显降低(P<0.05);d 30观察组三酰甘油(TG)水平明显降低(P<0.05)。治疗d 30观察组的TC和LDL-C明显低于对照组,高密度脂蛋白胆固醇(HDL-C)高于对照组(P<0.05)。与治疗前比较观察组hs-CRP治疗d 7明显降低,对照组d 30明显降低(P<0.05);观察组hs-CRP治疗d 7和d 30均明显低于对照组(P<0.01)。2组在治疗过程中均未出现不良反应。结论依折麦布联合普伐他汀比单用普伐他汀具有更好的降低LDL-C、TC和升高HDL-C的作用,且降低hs-CRP,具有良好的安全性。
Objective To observe the effects of ezetimibe and pravastatin on serum lipids and high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome. Methods 80 patients with acute coronary syndrome were divided into observation group (n = 42), pravastatin (20 mg.d-1) and ezetimibe 10 mg.d-1, and control group (n = 38) .d-1 and 2 groups were treated for 30 days. Two groups of patients before treatment, treatment d 7, d 30 blood lipids and high-sensitivity C-reactive protein. The two groups before and after treatment were compared between groups and between groups. Results The levels of TC and LDL-C in the observation group after d 7 treatment were significantly lower than those before treatment (P <0.05), while the levels of triglyceride (TG) in d 30 observation group were significantly decreased (P < 0.05). The TC and LDL-C in the treatment group of d30 were significantly lower than those in the control group, and the levels of high-density lipoprotein cholesterol (HDL-C) were higher than those in the control group (P <0.05). Compared with the pretreatment group, the hs-CRP in the observation group was significantly lower than that in the control group (P <0.05). The d 7 and d 30 in the observation group were significantly lower than those in the control group (P <0.01). No adverse reactions occurred in the two groups during the course of treatment. Conclusions Ezetimibe plus pravastatin has better safety and lower hs-CRP than pravastatin alone in lowering LDL-C, TC and increasing HDL-C.